

**Press Release APPOINTMENTS**

*Nantes, April 12, 2022*

**Two appointments and recruitments in prospect**

**within the XENOTHERA biotech company**

**In order to support its next steps of growth, the Nantes-based biotech company** [**XENOTHERA**](http://WWW.xenothera.com) **is strengthening its team with the arrival of two new people:**

**- Nathalie Auzerie, Head of Clinical Operations ;**

**- Corentin de Gastines, Director of Development.**

Une image contenant personne, femme, debout, dame

Description générée automatiquement

A graduate of IAE Bordeaux and with 30 years of experience in Clinical Research Organization (CRO) at Excelya, Nathalie Auzerie has held various positions: Clinical Research Associate, Clinical Project Manager, Quality Assurance Manager and CEO for the last 10 years. Prior to joining XENOTHERA, Nathalie was responsible for the proper conduct of clinical projects including planning, execution and monitoring to ensure patient safety, data integrity and compliance. This experience covers a multitude of therapeutic areas and types of clinical projects (Phase I to IV trials, Early Access, post-authorization studies) in France and internationally.

Nathalie Auzerie, 53 years old, joins XENOTHERA today as Clinical Operations Manager. Her main mission: to organize clinical operations under the medical direction, in order to ensure that the company achieves its clinical development objectives for the entire pipeline.

"Joining XENOTHERA to participate in the clinical development of highly innovative products and to be able to act in the interest of patients by actively addressing ever-existing medical needs in major fields such as immunology, oncology and COVID-19 is a real motivation! I am ready to take on new challenges by putting my expertise directly into a Biotech with very strong potential", declares Nathalie Auzerie, Head of Clinical Operations at XENOTHERA.

Une image contenant homme, personne, debout, complet

Description générée automatiquement

A graduate of HEI engineering school and Audencia business school, Corentin de Gastines began his career in a consulting firm and then Business Developer abroad for French companies. In 2016, he joined the Puy du Fou to participate in the transformation of a local company into an international group, holding the positions of Deputy Director of Development, Financial Director, Board Member and Project Director. Among other things, he structured and raised 200M€ for the construction of the Spanish park, structured the acceleration of investments in the Vendée site and set up the group's Chinese subsidiary in Shanghai.

Corentin de Gastines, 33, has joined the Nantes-based biotech as Director of Development. His role is to find licensing partnerships proposed mainly to pharmaceutical groups and financing to enable the marketing of products from XENOTHERA's portfolio to treat targeted pathologies.

"I am pleased with the trust placed in me by XENOTHERA in view of the 180° turn I have chosen in terms of my field. The company, different in its technology and visionary in its ambitious approach, has everything it takes to become a French pharmaceutical flagship; it's a wonderful adventure!" says Corentin de Gastines, XENOTHERA's Director of Development.

"The entire XENOTHERA team is delighted with these two appointments, which will enable us to support the rapid growth we have been experiencing for several months. Our ambition is to continue to respond to unmet medical needs by creating new therapeutic modes in numerous fields. Strengthening today is essential at this stage of the company's maturity," concludes Odile Duvaux, President of XENOTHERA.

In addition to these new arrivals, XENOTHERA plans to recruit 8 people in 2022, in R&D, production and legal affairs, to further structure its organization while maintaining its agility.

In less than 8 years, XENOTHERA has brought to the clinic LIS1, a new induction therapy in solid organ transplantation, targeting a market of more than $1 billion, and XAV19, its anti-COVID therapy for patients with moderate disease. The biotech has also established in vivo proof of concept in immuno-oncology and multi-drug resistant infections. It now has three products in its portfolio in the clinic.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

**ABOUT XENOTHERA :**

Founded in 2014, XENOTHERA is a Nantes-based biotech company that develops new therapeutic modes in many fields (immunology, oncology, viral infections...). The company develops treatments based on a unique proprietary technology for the production of "glyco-humanized" polyclonal antibodies. Its technological platform is built on a dual expertise in genetics and immunology. Several years ago, XENOTHERA identified the value of its antibodies as a treatment for coronavirus infections, which enabled it to propose a drug candidate against Covid at the beginning of the pandemic: XAV-19. This anti-Covid treatment, a polyclonal glyco-humanized antiviral antibody, is intended for patients suffering from moderate forms of the disease; its aim is to reduce the risk of aggravation and, in particular, to avoid a transfer to intensive care.

[The biotech also has a comprehensive portfolio of products, including LIS1, an immunosuppressant in transplantation that has been in the clinic since 2019, and XAB05, which entered the clinic in January 2022, for the treatment and prevention of multidrug-resistant bacteria infections.](https://www.izsogood.co/so/2eN_Jj2Wa/c?w=elODWJ4xfgqyxJM7DC_wCwJeEG5oitIPYFbqb3v8LYk.eyJ1IjoiaHR0cHM6Ly93d3cueGVub3RoZXJhLmNvbSIsInIiOiJkNmYxYmQ2Zi1mMTdkLTQxZGMtMGQzYi0wOTgzNWUzNDc2MDQiLCJtIjoibWFpbF9scCIsImMiOiI1ZWI1OGYxZi0yZDllLTQwOWQtOTA2OS03MzUyZTNjMTUwNmQifQ)

[XENOTHERA, a member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of the Pays de la Loire. The company has been supported since its creation by private investors, the Pays de la Loire Region and BPI France.](https://www.izsogood.co/so/2eN_Jj2Wa/c?w=elODWJ4xfgqyxJM7DC_wCwJeEG5oitIPYFbqb3v8LYk.eyJ1IjoiaHR0cHM6Ly93d3cueGVub3RoZXJhLmNvbSIsInIiOiJkNmYxYmQ2Zi1mMTdkLTQxZGMtMGQzYi0wOTgzNWUzNDc2MDQiLCJtIjoibWFpbF9scCIsImMiOiI1ZWI1OGYxZi0yZDllLTQwOWQtOTA2OS03MzUyZTNjMTUwNmQifQ)

For more information : www.xenothera.com

Follow XENOTHERA on social media:

Press contact

[IZsoGOOD](https://www.izsogood.co/so/84NtxNYtB/c?w=OX_Ir9B4VrGpjgP1Sf4K4_GH7rhfVWrnTzK791Jtc_U.eyJ1IjoiaHR0cDovL3d3dy5penNvZ29vZC5jbyIsInIiOiI1MWM2MmMxYi04MTJiLTRkNmUtOTY2OS1mMDEwMjk5NWFhNmUiLCJtIjoibWFpbCIsImMiOiI1ZWI1OGYxZi0yZDllLTQwOWQtOTA2OS03MzUyZTNjMTUwNmQifQ)

Ingrid Zémor & Elise Plat

06 73 72 99 92 / 06 79 98 48 94

[xenothera@izsogood.co](https://www.izsogood.co/so/84NtxNYtB/c?w=y6-MgKEO_WqZmJzUzbgkf9bjY3ohF4oU_5bU4SJD6qg.eyJ1IjoibWFpbHRvOnhlbm90aGVyYUBpenNvZ29vZC5jbyIsInIiOiI1MWM2MmMxYi04MTJiLTRkNmUtOTY2OS1mMDEwMjk5NWFhNmUiLCJtIjoibWFpbCIsImMiOiI1ZWI1OGYxZi0yZDllLTQwOWQtOTA2OS03MzUyZTNjMTUwNmQifQ)